SHORT-TERM EFFECT OF RECOMBINANT HUMAN GROWTH-HORMONE IN PATIENTS WITH ALCOHOLIC CIRRHOSIS
SHORT-TERM EFFECT OF RECOMBINANT HUMAN GROWTH-HORMONE IN PATIENTS WITH ALCOHOLIC CIRRHOSIS
复制标题
DOI：
10.1016/s0168-8278(94)80228-9
复制
发表时间：
1994-11-01
影响因子：
25.7
通讯作者：
SKAKKEBAEK, NE
中科院分区：
文献类型：
--
作者：
MOLLER, S;BECKER, U;SKAKKEBAEK, NE
由于生长激素具有对蛋白质代谢具有活性的合成代谢特性，因此对慢性肝病患者具有潜在益处，我们确定了重组人生长激素对胰岛素样生长因子-I（ICF-I）及其特异性结合蛋白和肝功能的代谢作用。20例连续肝硬化患者随机接受重组人生长激素（Norditropin，4 I.U.每日两次）皮下注射6周（n=10）或常规药物治疗（n=10）。重组人生长激素组血清胰岛素样生长因子-I浓度在3周后升高（P
As growth hormone possesses anabolic properties that are active on protein metabolism, and thus of potential benefit to patients with chronic liver disease, we determined the metabolic effects of recombinant human growth hormone on insulin-like growth factor-I (ICF-I) its specific binding proteins, and liver function. Twenty consecutive patients with cirrhosis were randomized to recombinant human growth hormone (Norditropin, 4 I.U. twice daily) subcutaneously for 6 weeks (n=10) or conventional medical treatment (n=10). The serum concentrations of insulin-like growth factor-I in the recombinant human growth hormone group increased after 3 (p